Ampreloxetine Funding - Schedule of Future Royalty Payment Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Development and Collaboration Agreement
Beginning balance	$ 27,788
Non-cash interest expense accretion	2,546	$ 2,350
Ending balance	30,334	27,788
Ampreloxetine Royalty Rights
Development and Collaboration Agreement
Beginning balance	27,788
Non-cash interest expense accretion	2,546
Ending balance	$ 30,334	$ 27,788